Juvenile rheumatoid arthritis with systemic onset, hip Save

Juvenile Rheumatoid Arthritis with Systemic Onset and Hip Involvement

Juvenile Rheumatoid Arthritis (JRA) is a chronic autoimmune disease that affects children under the age of 16. It is characterized by joint inflammation, stiffness, and pain. JRA with systemic onset, also known as Still's disease, is a rare form of JRA that affects the entire body, including the joints, organs, and tissues. Hip involvement is common in JRA with systemic onset, and it can lead to significant disability if left untreated.

The exact cause of JRA with systemic onset is unknown. However, it is believed to be a combination of genetic and environmental factors. Children with JRA with systemic onset may experience fever, rash, and inflammation of the lymph nodes, liver, and spleen. Hip involvement may cause limping, pain, and stiffness in the hip joint.

Early diagnosis and treatment are crucial in managing JRA with systemic onset and hip involvement. A thorough physical examination, blood tests, and imaging studies are usually performed to confirm the diagnosis. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents.

1. NSAIDs: These medications are used to reduce inflammation, pain, and fever. They are usually the first line of treatment for JRA with systemic onset and hip involvement.
2. Corticosteroids: These medications are used to reduce inflammation and pain. They are usually prescribed in low doses for a short period to avoid side effects.
3. DMARDs: These medications are used to slow down the progression of JRA. They are usually prescribed when NSAIDs and corticosteroids are not effective.
4. Biologic agents: These medications are used to target specific proteins that contribute to inflammation. They are usually prescribed when other medications are not effective.

Physical therapy and exercise are also important in managing JRA with systemic onset and hip involvement. A physical therapist can design an exercise program that can help improve joint mobility, strength, and flexibility. It is important to avoid activities that can cause stress on the hip joint, such as running and jumping.

In conclusion, JRA with systemic onset and hip involvement is a rare form of JRA that can lead to significant disability if left untreated. Early diagnosis and treatment are crucial in managing the disease. Treatment options include NSAIDs, corticosteroids, DMARDs, and biologic agents. Physical therapy and exercise are also important in managing the disease and improving joint mobility, strength, and flexibility.